Motivated by currently available treatment against ND involving the inhibitors of acetylcholinesterase (AChE) and N-methyl-D-aspartate receptor (NMDAR), administered also in combination, we developed a dually-acting compounds based on 1,2,3,4-tetrahydro-9-aminoacridine (tacrine) structure and confirmed their neuropsychopharmacological and drug-like properties for potential therapeutic use. Technology is being in in-vivo validated.
University Hospital Hradec Králové, Institute of Physiology CAS, National Institute of Experimental medicine CAS (projects NU20-08-00296, IT4Neuro(degeneration) CZ.02.1.01/0.0/0.0/18_069/0010054).
IP Status: Czech patent applications PV 2021-34 and PV 20201-35 (priority date 26. 1. 2021).
A dosage form with controlled release of glucose with 4, 6 and 8 hours lag time offering a chance to substitute snacks or other meals in advance. The variables of the dosage form were an optimal diameter of the pellet, resistance of the coat, volume, taste and form acceptable for swallowing. These variables were refined via pharmaceutical methods for optimal efficiency in patient use.
University Hospital Hradec Králové, University of Veterinary and Pharmaceutical Sciences Brno (projects GAMA TACR TG02010020, NT14472).
IP Status: EP2994111, US2016081941, WO2014180453, czech patent application PV 2016-338, know-how.
Thickener for food and beverages intended for the dietary process of dysphagia (swallowing difficulties). The complex preparations meet the requirements for higher-generation additives to thicken enteral nutrition and serve mainly in the prevention of aspiration, which can endanger patients' lives. Newly created products are also a source of energy and do not interfere with ions or ionic binding of drugs.
University Hospital HK (projects MIT - FV40300 - Biotechnological solution of physical-chemical optimization of enteral preparations in the provision of dysphagia 2019 - 2022).
IP Status: utility models 33712 and 34241 (priority 18 October 2019 and 11 May 2020).